Recipharm to expand manufacturing facility and R&D team

Swedish contract development and manufacturing organization Recipharm (STO: RECI) is to invest more than 1.2 million euros ($1.33 million) to enhance its small-scale active pharmaceutical ingredient (API) development and manufacturing capabilities in Paderno Dugnano, Italy.

The improvements are in response to growing demand for Recipharm’s custom synthesis and early phase API manufacturing capabilities and include a new kilo laboratory, which is fully compliant with Good Manufacturing Practice (GMP), to enhance the output of the facility’s existing laboratories.

Recipharm’s team in Paderno Dugnano specializes in the scale-up and manufacture of APIs for all clinical phases, from gram to kilo and pilot scale to commercial supply.